|
시장보고서
상품코드
2052271
다낭성난소증후군(PCOS) 치료 시장 : 약물 종류별, 유통 채널별, 지역별Polycystic Ovary Syndrome (PCOS) Treatment Market, By Drug Class, By Distribution Channel, By Region |
||||||
다낭성난소증후군(PCOS) 치료 시장은 2026년에 12억 5,570만 달러로 추정되며, 2033년까지 17억 7,390만 달러에 달할 것으로 예상됩니다. 2026년부터 2033년까지 CAGR 5.1%로 성장할 것으로 전망됩니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도: | 2025년 | 2026년 시장 규모: | 12억 5,570만 달러 |
| 과거 데이터 기간: | 2020-2024년 | 예측 기간: | 2026-2033년 |
| 2026년부터 2033년까지 예측 기간 CAGR: | 5.10% | 2033년 시장 규모 예측: | 17억 7,390만 달러 |
다낭성난소증후군(PCOS)은 내분비계 질환의 결과로 난소에 액체로 채워진 작은 낭종이 형성되는 질환으로 설명할 수 있습니다. PCOS를 가진 여성은 특히 가임기 여성에게 영향을 받습니다. PCOS 진단을 받은 여성은 유산, 임신성 당뇨, 임신성 고혈압, 자간전증, 조산의 위험이 높아집니다. 또한, PCOS 여성은 생리주기 불규칙, 안드로겐(성호르몬) 수치 상승, 다모증, 여드름, 비만 등의 증상이 나타날 수 있습니다.
PCOS를 가진 여성은 심각한 건강 문제가 발생할 위험이 높습니다. 제2형 당뇨병, 고혈압, 심장 및 혈관 질환, 자궁암 등이 이에 해당합니다. PCOS를 앓고 있는 여성은 임신(불임)에 어려움을 겪는 경우가 많습니다.
시장 역학
경구 피임약의 효과적인 사용과 제품 가치의 증가는 예측 기간 동안 다낭성난소증후군(PCOS) 치료 시장을 견인할 수 있습니다. 예를 들어, 2022년 8월 NCBI에 게재된 논문에 따르면, PCOS 치료에서 경구피임약(OC)의 주요 작용 기전은 월경 조절에 있다고 합니다. 이 약들은 테스토스테론 수치를 낮춤으로써 다모증과 여드름도 감소시킵니다. 따라서 경구 피임약은 다낭성난소증후군의 일차적 치료법으로 사용되고 있습니다.
또한, 다낭성난소증후군(PCOS) 치료의 새로운 메커니즘에 대한 인식이 높아짐에 따라 예측 기간 동안 시장 성장을 촉진할 것으로 예상됩니다. 예를 들어, 2021년 11월 중국 산부인과에서 발표한 연구에 따르면, 전기침(EA) 중재는 지질대사 조절인자인 SREBP1의 조절을 통해 인슐린 저항성(IR), 미토콘드리아 기능 장애 및 산화 스트레스를 개선하여 쥐의 PCOS 유사 증상을 완화시키는 것으로 나타났습니다. 완화하는 것으로 나타났습니다. 이번 연구 결과는 PCOS 치료에서 EA의 새로운 보호 메커니즘을 밝혀냈습니다.
본 조사의 주요 특징
- 이 보고서는 각 부문의 잠재적 수익 기회를 밝히고, 이 시장에서 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한 시장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업이 채택한 경쟁 전략에 대한 중요한 인사이트를 제공합니다.
- 이 보고서는 다음과 같은 매개 변수(회사 하이라이트, 제품 포트폴리오, 주요 하이라이트, 재무 성과, 전략)를 기반으로 세계 다낭성난소증후군(PCOS) 치료 시장의 주요 업체를 분석합니다.
- 세계 다낭성난소증후군(PCOS) 치료 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입자, 재무 분석가 등 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계 다낭성난소증후군(PCOS) 치료 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 쉽게 내릴 수 있을 것입니다.
목차
제1장 조사 목적과 가정
제2장 시장 전망
제3장 시장 역학·규제·동향 분석
제4장 세계의 다낭성난소증후군(PCOS) 치료 시장 : 약물 종류별, 2021-2033년
제5장 세계의 다낭성난소증후군(PCOS) 치료 시장 : 유통 채널별, 2021-2033년
제6장 세계의 다낭성난소증후군(PCOS) 치료 시장 : 지역별, 2021-2033년
제7장 경쟁 구도
제8장 섹션
KSM 26.06.16Polycystic Ovary Syndrome (PCOS) Treatment Market is estimated to be valued at USD 1,255.7 Mn in 2026 and is expected to reach USD 1,773.9 Mn by 2033, growing at a compound annual growth rate (CAGR) of 5.1% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 1,255.7 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 5.10% | 2033 Value Projection: | USD 1,773.9 Mn |
Polycystic Ovarian Syndrome (PCOS) can be described as small sacs filled with fluid develop on the ovaries as a result of the endocrine system condition. Women with PCOS who are of childbearing age are affected. PCOS-positive women are more likely to experience miscarriage, gestational diabetes, pregnancy-induced hypertension, preeclampsia, and early birth. Moreover, women with PCOS may experience irregular menstrual cycles, elevated androgen (sex hormone) levels, excessive hair growth, acne, and obesity.
Women who have PCOS are more likely to develop serious health issues. These include type 2 diabetes, high blood pressure, heart and blood vessel problems, and uterine cancer. Women suffering from PCOS frequently struggle to conceive (fertility).
Market Dynamics
Effective use of oral contraceptives and increasing product value can drive the polycystic ovary syndrome (PCOS) treatment market over the forecast period. For instance, in August 2022, an article was published in the NCBI, according to which, for the treatment of PCOS, the major mechanism of action of oral contraceptives (OCs) is to control menstruation. These drugs also reduce hirsutism and acne by lowering testosterone levels. Thus, oral contraceptives are primary treatment for the polycystic ovary syndrome.
Moreover, rising awareness about novel mechanisms in the treatment of Polycystic Ovary Syndrome (PCOS) is anticipated to boost the growth of the market over the forecast period. For instance, according to research study published by Department of Obstetrics and Gynecology, China in November 2021, stated that the electroacupuncture (EA) intervention alleviated PCOS-like symptoms in rats by improving IR, mitochondrial dysfunction and oxidative stress through regulation of SREBP1, a regulator of lipid metabolism. The study findings illuminate the novel protective mechanisms of EA in the treatment of PCOS.
Key features of the study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the Global Polycystic Ovary Syndrome (PCOS) Treatment Market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study Key companies covered as a part of this study Sanofi S.A., Amneal Pharmaceuticals, Inc., Laurus Labs Limited, Zydus Pharmaceuticals, Inc., Prasco Laboratories, Dr. Reddy's Laboratories, Cadila Pharmaceuticals, Novartis International AG, Concordia Pharmaceuticals Inc., Evotec SE, Covis Pharmaceuticals, Inc., Cardinal Health, Aphena Pharma Solutions Tennessee, Inc., Mylan N.V., McKesson Corporation, Teva Pharmaceutical Industries Ltd, Lupin Pharmaceutical and Sun Pharmaceutical Industries Ltd., Bayer AG, and other prominent players Insights from this report will allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global Polycystic Ovary Syndrome (PCOS) Treatment Market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Polycystic Ovary Syndrome (PCOS) Treatment Market
Market Segmentation
- By Drug Class (Revenue, USD Mn, 2021 - 2033)
- Oral contraceptives
- Insulin Sensitizing Agents
- Anti-Depressants
- Ornithine Decarboxylase Inhibitors
- Aromatase Inhibitors & SERMs
- Diuretics
- By Distribution Channel (Revenue, USD Mn, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Region (Revenue, USD Mn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Company Profiles
- Sanofi S.A.
- Amneal Pharmaceuticals, Inc.
- Laurus Labs Limited
- Zydus Pharmaceuticals, Inc.
- Prasco Laboratories
- Reddy's Laboratories
- Cadila Pharmaceuticals
- Novartis International AG
- Concordia Pharmaceuticals Inc.
- Covis Pharmaceuticals, Inc.
- Cardinal Health
- Aphena Pharma Solutions Tennessee, Inc.
- Mylan N.V.
- McKesson Corporation
- Teva Pharmaceutical Industries Ltd
- Lupin Pharmaceutical
- Sun Pharmaceutical Industries Ltd.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Drug Class
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Attractiveness Analysis
- Market Opportunities
- Epidemiology
- Regulatory Scenario
- Product Launches
- Merger, Acquisition, Collaborations
- Key Developments
- Market Trends
- PEST Analysis
- PORTER'S Analysis
- Risk and Adverse Effects
- New Investments by Major Market Players
- Pipeline Analysis
- Supply Chain Analysis
- Pricing Analysis
- Brand Analysis
4. Global Polycystic Ovary Syndrome (PCOS) Treatment Market, By Drug Class, 2021 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Oral contraceptives
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Insulin Sensitizing Agents
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Anti- Depressants
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Ornithine Decarboxylase Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Aromatase Inhibitors & SERMs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Diuretics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
5. Global Polycystic Ovary Syndrome (PCOS) Treatment Market, By Distribution Channel, 2021 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033(%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segments Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
6. Global Polycystic Ovary Syndrome (PCOS) Treatment Market, By Region, 2021 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033(%)
- Y-o-Y Growth Analysis, For Regions, 2021 - 2033
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Mn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Mn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Mn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 - 2033, (USD Mn)
- North Africa
- Central Africa
- South Africa
7. Competitive Landscape
- Sanofi S.A.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Amneal Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Laurus Labs Limited
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Zydus Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Prasco Laboratories
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Reddy's Laboratories
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Cadila Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Novartis International AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Concordia Pharmaceuticals Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Covis Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Cardinal Health
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Aphena Pharma Solutions Tennessee, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Mylan N.V.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- McKesson Corporation
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Teva Pharmaceutical Industries Ltd
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Lupin Pharmaceutical
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Sun Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
8. Section
- Research Methodology
- About Us
